A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis
Key facts
- Who runs it
- Shanghai BDgene Co., Ltd.
- Where
- China3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1
- People taking part
- 16 people, planned
- Started
- 4 Sept 2023
- Ended
- 13 Mar 2026
- Type of study
- Interventional, 5 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- BD111 Injection (Investigative New Drug)
- Triple-drugs therapy of HSV-1 stromal keratitis
- Record updated
- 18 May 2025
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (29)Hide the full registry criteria
Who can take part
- Aged 18 to 70 years old
- Clinically diagnosed patients with recurrent herpes simplex virus type I stromal keratitis (HSK). Definition of recurrence: the patient had been diagnosed with HSK and received "local antiviral eye drugs and oral antiviral drugs + local glucocorticoid eye drops" for 3 weeks with successful clinical efficacy. Before enrollment, the clinical recurrence of HSK occurred again with symptoms including tearing, photophobia, pain, blurred vision and foreign body sensation, and signs as recurrence of active inflammatory lesions examined by slit lamp
- HSV-1 nucleic acid test (qPCR method) positive
- No use of other systemic antiviral drugs or corticosteroids within 48 hours before enrollment
- No systemic immune diseases
- Good eyelid structure and blinking function
- Eye structure and function assessment showing potential for visual recovery
- No retinal detachment
- No history of corneal trauma
- The best visual acuity in the fellow eye (BCVA) ≥ 38 (ETDRS)
- Fertile males or females must use highly effective contraceptive methods, such as, oral contraceptives, intrauterine devices, abstinence, or barrier contraception combined with spermicides, during the trial and continue contraception for 12 months after administration
- Participants voluntarily join the study, sign an informed consent form, have good compliance, and cooperate with follow-up visits
Who cannot take part
- Active ocular infection caused by other pathogens in the target eye or the fellow eye within 30 days before enrollment, including but not limited to infectious conjunctivitis, keratitis, scleritis, and endophthalmitis
- Previous corneal transplant surgery in the study eye
- Participation in other drug or medical device clinical trials at present
- Alcohol or drug abuse
- Any medicine or food allergic history
- Severe dry eye disease
- Patients with systemic autoimmune diseases
- Severe diseases in the major organs including but not limited to cardiovascular, lung, liver, kidney, or other uncontrolled diseases
- HIV infection
- Signs of systemic infection before enrollment, including fever and receiving antibiotic treatment (systemic infection in this trial is defined as abnormal values in white blood cells, lymphocytes, and neutrophils in routine blood tests)
- Patients with bilateral viral keratitis
- Absence of tear film and blinking function
- Ocular surface tumor
- Glaucoma
- Pregnant and lactating women (pregnancy in this trial is defined as a positive urine or blood pregnancy test)
- Lack of compliance with the trial or the ability to sign an informed consent form
- Other situations deemed unsuitable for participation in the trial by the investigator
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This Phase I study is intended to evaluate the safety, tolerability, PK/PD profiles and preliminary efficacy via corneal intrastromal administration in patients with herpes simplex virus-1 stromal keratitis (HSK), with a dose exploration of four ascending doses of BD111 (investigative drug product).
The 5 groups in the trial
- BD111 dose 1 groupTreatment being tested
1.25E+06 TU/eye
Treatment: BD111 Injection (Investigative New Drug)
- BD111 dose 2 groupTreatment being tested
2.5E+06 TU/eye
Treatment: BD111 Injection (Investigative New Drug)
- BD111 dose 3 groupTreatment being tested
5.0E+06TU/eye
Treatment: BD111 Injection (Investigative New Drug)
- BD111 dose 4 groupTreatment being tested
10E+06 TU/eye
Treatment: BD111 Injection (Investigative New Drug)
- Positive control groupExisting treatment, for comparison
Triple-drugs therapy group: "Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops" for 3 weeks.
Treatment: Triple-drugs therapy of HSV-1 stromal keratitis
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Open-label, Single Dose, Phase Ⅰ Trial to Evaluate the Safety, Tolerability and Prelinminary Efficacy of BD111 in Patients With Herpes Simplex Virus Type I Stromal Keratitis in China
- Record updated
- 18 May 2025